Skip to main content
. Author manuscript; available in PMC: 2019 Oct 9.
Published in final edited form as: J Am Coll Cardiol. 2018 Oct 9;72(15):1856–1869. doi: 10.1016/j.jacc.2018.07.071

Figure 4: Summary of Renal Benefits in Major Recent Trials of SGTL2-i and GLP-1 RA.

Figure 4:

Renal outcomes were all favorably reduced by therapy in EMPA-REG, CANVAS Program, LEADER, and SUSTAIN-6. All trials used a roughly similar composite for adverse renal outcomes including progression of albuminuria.